Topoisomerase inhibitors are a new class of therapeutic drugs whose mechanism of action is to bind to the DNA-topoisomerase complex, causing DNA double-strand breaks and ultimately leading to cell apoptosis. As an ADC payload, topoisomerase is an alternative to the tubulin inhibitors widely used in ADCs in clinical trials.
The global Topoisomerase Inhibitors market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Topoisomerase Inhibitors Industry Forecast” looks at past sales and reviews total world Topoisomerase Inhibitors sales in 2023, providing a comprehensive analysis by region and market sector of projected Topoisomerase Inhibitors sales for 2024 through 2030. With Topoisomerase Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Topoisomerase Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Topoisomerase Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Topoisomerase Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Topoisomerase Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Topoisomerase Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Topoisomerase Inhibitors.
United States market for Topoisomerase Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Topoisomerase Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Topoisomerase Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Topoisomerase Inhibitors players cover Roche, Mundipharma, Purdue Pharma, Debiopharm, Ipsen Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Topoisomerase Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Etoposide
Irinotecan
Topotecan
Other
Segmentation by Application:
Hospital
Clinic
Home Care
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Roche
Mundipharma
Purdue Pharma
Debiopharm
Ipsen Pharma
TopoGEN
Novartis
Hikma Pharmaceuticals
Viatris
Pfizer
Merrimack Pharmaceuticals
Amgen
Johnson & Johnson
BioMérieux
Promega
Takeda Pharmaceutical
Merck KGaA
Cipla
Teva Pharmaceuticals Indutries
Key Questions Addressed in this Report
What is the 10-year outlook for the global Topoisomerase Inhibitors market?
What factors are driving Topoisomerase Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Topoisomerase Inhibitors market opportunities vary by end market size?
How does Topoisomerase Inhibitors break out by Type, by Application?

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Topoisomerase Inhibitors Annual Sales 2019-2030 2.1.2 World Current & Future Analysis for Topoisomerase Inhibitors by Geographic Region, 2019, 2023 & 2030 2.1.3 World Current & Future Analysis for Topoisomerase Inhibitors by Country/Region, 2019, 2023 & 2030 2.2 Topoisomerase Inhibitors Segment by Type 2.2.1 Etoposide 2.2.2 Irinotecan 2.2.3 Topotecan 2.2.4 Other 2.3 Topoisomerase Inhibitors Sales by Type 2.3.1 Global Topoisomerase Inhibitors Sales Market Share by Type (2019-2024) 2.3.2 Global Topoisomerase Inhibitors Revenue and Market Share by Type (2019-2024) 2.3.3 Global Topoisomerase Inhibitors Sale Price by Type (2019-2024) 2.4 Topoisomerase Inhibitors Segment by Application 2.4.1 Hospital 2.4.2 Clinic 2.4.3 Home Care 2.5 Topoisomerase Inhibitors Sales by Application 2.5.1 Global Topoisomerase Inhibitors Sale Market Share by Application (2019-2024) 2.5.2 Global Topoisomerase Inhibitors Revenue and Market Share by Application (2019-2024) 2.5.3 Global Topoisomerase Inhibitors Sale Price by Application (2019-2024) 3 Global by Company 3.1 Global Topoisomerase Inhibitors Breakdown Data by Company 3.1.1 Global Topoisomerase Inhibitors Annual Sales by Company (2019-2024) 3.1.2 Global Topoisomerase Inhibitors Sales Market Share by Company (2019-2024) 3.2 Global Topoisomerase Inhibitors Annual Revenue by Company (2019-2024) 3.2.1 Global Topoisomerase Inhibitors Revenue by Company (2019-2024) 3.2.2 Global Topoisomerase Inhibitors Revenue Market Share by Company (2019-2024) 3.3 Global Topoisomerase Inhibitors Sale Price by Company 3.4 Key Manufacturers Topoisomerase Inhibitors Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Topoisomerase Inhibitors Product Location Distribution 3.4.2 Players Topoisomerase Inhibitors Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Topoisomerase Inhibitors by Geographic Region 4.1 World Historic Topoisomerase Inhibitors Market Size by Geographic Region (2019-2024) 4.1.1 Global Topoisomerase Inhibitors Annual Sales by Geographic Region (2019-2024) 4.1.2 Global Topoisomerase Inhibitors Annual Revenue by Geographic Region (2019-2024) 4.2 World Historic Topoisomerase Inhibitors Market Size by Country/Region (2019-2024) 4.2.1 Global Topoisomerase Inhibitors Annual Sales by Country/Region (2019-2024) 4.2.2 Global Topoisomerase Inhibitors Annual Revenue by Country/Region (2019-2024) 4.3 Americas Topoisomerase Inhibitors Sales Growth 4.4 APAC Topoisomerase Inhibitors Sales Growth 4.5 Europe Topoisomerase Inhibitors Sales Growth 4.6 Middle East & Africa Topoisomerase Inhibitors Sales Growth 5 Americas 5.1 Americas Topoisomerase Inhibitors Sales by Country 5.1.1 Americas Topoisomerase Inhibitors Sales by Country (2019-2024) 5.1.2 Americas Topoisomerase Inhibitors Revenue by Country (2019-2024) 5.2 Americas Topoisomerase Inhibitors Sales by Type (2019-2024) 5.3 Americas Topoisomerase Inhibitors Sales by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Topoisomerase Inhibitors Sales by Region 6.1.1 APAC Topoisomerase Inhibitors Sales by Region (2019-2024) 6.1.2 APAC Topoisomerase Inhibitors Revenue by Region (2019-2024) 6.2 APAC Topoisomerase Inhibitors Sales by Type (2019-2024) 6.3 APAC Topoisomerase Inhibitors Sales by Application (2019-2024) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Topoisomerase Inhibitors by Country 7.1.1 Europe Topoisomerase Inhibitors Sales by Country (2019-2024) 7.1.2 Europe Topoisomerase Inhibitors Revenue by Country (2019-2024) 7.2 Europe Topoisomerase Inhibitors Sales by Type (2019-2024) 7.3 Europe Topoisomerase Inhibitors Sales by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Topoisomerase Inhibitors by Country 8.1.1 Middle East & Africa Topoisomerase Inhibitors Sales by Country (2019-2024) 8.1.2 Middle East & Africa Topoisomerase Inhibitors Revenue by Country (2019-2024) 8.2 Middle East & Africa Topoisomerase Inhibitors Sales by Type (2019-2024) 8.3 Middle East & Africa Topoisomerase Inhibitors Sales by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Topoisomerase Inhibitors 10.3 Manufacturing Process Analysis of Topoisomerase Inhibitors 10.4 Industry Chain Structure of Topoisomerase Inhibitors 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Topoisomerase Inhibitors Distributors 11.3 Topoisomerase Inhibitors Customer 12 World Forecast Review for Topoisomerase Inhibitors by Geographic Region 12.1 Global Topoisomerase Inhibitors Market Size Forecast by Region 12.1.1 Global Topoisomerase Inhibitors Forecast by Region (2025-2030) 12.1.2 Global Topoisomerase Inhibitors Annual Revenue Forecast by Region (2025-2030) 12.2 Americas Forecast by Country (2025-2030) 12.3 APAC Forecast by Region (2025-2030) 12.4 Europe Forecast by Country (2025-2030) 12.5 Middle East & Africa Forecast by Country (2025-2030) 12.6 Global Topoisomerase Inhibitors Forecast by Type (2025-2030) 12.7 Global Topoisomerase Inhibitors Forecast by Application (2025-2030) 13 Key Players Analysis 13.1 Roche 13.1.1 Roche Company Information 13.1.2 Roche Topoisomerase Inhibitors Product Portfolios and Specifications 13.1.3 Roche Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.1.4 Roche Main Business Overview 13.1.5 Roche Latest Developments 13.2 Mundipharma 13.2.1 Mundipharma Company Information 13.2.2 Mundipharma Topoisomerase Inhibitors Product Portfolios and Specifications 13.2.3 Mundipharma Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.2.4 Mundipharma Main Business Overview 13.2.5 Mundipharma Latest Developments 13.3 Purdue Pharma 13.3.1 Purdue Pharma Company Information 13.3.2 Purdue Pharma Topoisomerase Inhibitors Product Portfolios and Specifications 13.3.3 Purdue Pharma Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.3.4 Purdue Pharma Main Business Overview 13.3.5 Purdue Pharma Latest Developments 13.4 Debiopharm 13.4.1 Debiopharm Company Information 13.4.2 Debiopharm Topoisomerase Inhibitors Product Portfolios and Specifications 13.4.3 Debiopharm Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.4.4 Debiopharm Main Business Overview 13.4.5 Debiopharm Latest Developments 13.5 Ipsen Pharma 13.5.1 Ipsen Pharma Company Information 13.5.2 Ipsen Pharma Topoisomerase Inhibitors Product Portfolios and Specifications 13.5.3 Ipsen Pharma Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.5.4 Ipsen Pharma Main Business Overview 13.5.5 Ipsen Pharma Latest Developments 13.6 TopoGEN 13.6.1 TopoGEN Company Information 13.6.2 TopoGEN Topoisomerase Inhibitors Product Portfolios and Specifications 13.6.3 TopoGEN Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.6.4 TopoGEN Main Business Overview 13.6.5 TopoGEN Latest Developments 13.7 Novartis 13.7.1 Novartis Company Information 13.7.2 Novartis Topoisomerase Inhibitors Product Portfolios and Specifications 13.7.3 Novartis Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.7.4 Novartis Main Business Overview 13.7.5 Novartis Latest Developments 13.8 Hikma Pharmaceuticals 13.8.1 Hikma Pharmaceuticals Company Information 13.8.2 Hikma Pharmaceuticals Topoisomerase Inhibitors Product Portfolios and Specifications 13.8.3 Hikma Pharmaceuticals Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.8.4 Hikma Pharmaceuticals Main Business Overview 13.8.5 Hikma Pharmaceuticals Latest Developments 13.9 Viatris 13.9.1 Viatris Company Information 13.9.2 Viatris Topoisomerase Inhibitors Product Portfolios and Specifications 13.9.3 Viatris Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.9.4 Viatris Main Business Overview 13.9.5 Viatris Latest Developments 13.10 Pfizer 13.10.1 Pfizer Company Information 13.10.2 Pfizer Topoisomerase Inhibitors Product Portfolios and Specifications 13.10.3 Pfizer Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.10.4 Pfizer Main Business Overview 13.10.5 Pfizer Latest Developments 13.11 Merrimack Pharmaceuticals 13.11.1 Merrimack Pharmaceuticals Company Information 13.11.2 Merrimack Pharmaceuticals Topoisomerase Inhibitors Product Portfolios and Specifications 13.11.3 Merrimack Pharmaceuticals Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.11.4 Merrimack Pharmaceuticals Main Business Overview 13.11.5 Merrimack Pharmaceuticals Latest Developments 13.12 Amgen 13.12.1 Amgen Company Information 13.12.2 Amgen Topoisomerase Inhibitors Product Portfolios and Specifications 13.12.3 Amgen Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.12.4 Amgen Main Business Overview 13.12.5 Amgen Latest Developments 13.13 Johnson & Johnson 13.13.1 Johnson & Johnson Company Information 13.13.2 Johnson & Johnson Topoisomerase Inhibitors Product Portfolios and Specifications 13.13.3 Johnson & Johnson Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.13.4 Johnson & Johnson Main Business Overview 13.13.5 Johnson & Johnson Latest Developments 13.14 BioMérieux 13.14.1 BioMérieux Company Information 13.14.2 BioMérieux Topoisomerase Inhibitors Product Portfolios and Specifications 13.14.3 BioMérieux Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.14.4 BioMérieux Main Business Overview 13.14.5 BioMérieux Latest Developments 13.15 Promega 13.15.1 Promega Company Information 13.15.2 Promega Topoisomerase Inhibitors Product Portfolios and Specifications 13.15.3 Promega Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.15.4 Promega Main Business Overview 13.15.5 Promega Latest Developments 13.16 Takeda Pharmaceutical 13.16.1 Takeda Pharmaceutical Company Information 13.16.2 Takeda Pharmaceutical Topoisomerase Inhibitors Product Portfolios and Specifications 13.16.3 Takeda Pharmaceutical Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.16.4 Takeda Pharmaceutical Main Business Overview 13.16.5 Takeda Pharmaceutical Latest Developments 13.17 Merck KGaA 13.17.1 Merck KGaA Company Information 13.17.2 Merck KGaA Topoisomerase Inhibitors Product Portfolios and Specifications 13.17.3 Merck KGaA Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.17.4 Merck KGaA Main Business Overview 13.17.5 Merck KGaA Latest Developments 13.18 Cipla 13.18.1 Cipla Company Information 13.18.2 Cipla Topoisomerase Inhibitors Product Portfolios and Specifications 13.18.3 Cipla Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.18.4 Cipla Main Business Overview 13.18.5 Cipla Latest Developments 13.19 Teva Pharmaceuticals Indutries 13.19.1 Teva Pharmaceuticals Indutries Company Information 13.19.2 Teva Pharmaceuticals Indutries Topoisomerase Inhibitors Product Portfolios and Specifications 13.19.3 Teva Pharmaceuticals Indutries Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024) 13.19.4 Teva Pharmaceuticals Indutries Main Business Overview 13.19.5 Teva Pharmaceuticals Indutries Latest Developments 14 Research Findings and Conclusion